At the request of the Agence nationale de sécurité du médicament et des produits de santé, the establishments mentioned in the first paragraph of Article R. 1221-40 shall collect and keep all the information relating to haemovigilance and transfusion safety to which they have access and which concerns :
1° Scheduled autologous transfusions ;
2° Pre-transfusion and, where appropriate, post-transfusion examinations carried out on the patient;
3° The administration, as part of the same treatment, of a blood-derived medicinal product and a labile blood product;
4° The storage, for subsequent analysis, of biological samples taken from the patient.